Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

MAY 26, 2015 - Benzinga

A Must Read - Share

Amgen, AstraZeneca End Development Pact; Shares Sink

Amgen, Inc. (NASDAQ: AMGN) shares lost about 2.8 percent Tuesday on fallout from the termination of a three-year-old development pact with AstraZeneca plc (NYSE: AZN). Amgen closed at $159.02, off $4.57; AstraZeneca declined 2.5 percent to $67.68.

Tags: Amgen, AstraZeneca End Development Pact; Shares Sink,  Amgen Latest News

MAY 26, 2015 - Investopedia

A Must Read - Share

Amgen Gets 1 Step Closer to Another Blockbuster

A key European advisory committee has just thrown its support behind approval for Amgen's (NASDAQ: AMGN) Repatha, a new medicine that could end up significantly changing how doctors battle high cholesterol. Last week's decision by the EU's Committee for Medicinal Products for Human Use helps clear the way for a formal approval of Repatha later this year, and may suggest that ...

Tags: Amgen Gets 1 Step Closer to Another Blockbuster,  Amgen Latest News

MAY 26, 2015 - Benzinga

A Must Read - Share

Morgan Stanley Found This 'Unexpected Negative' At Amgen

In a report published Tuesday, Morgan Stanley analysts maintained an Equal-Weight rating on Amgen Inc (NASDAQ: AMGN), while reducing the price target from $179 to $171. Latest Ratings for AMGN DateFirmActionFromTo Apr 2015JefferiesMaintainsBuy Apr 2015NomuraMaintainsBuy Jan 2015BarclaysInitiates Coverage onEqual-weight View More Analyst Ratings for AMGN View the Latest Analyst Ratings

Tags: Morgan Stanley Found This 'Unexpected Negative' At Amgen,  Amgen Latest News

MAY 26, 2015 - Business Insider

A Must Read - Share

AstraZeneca hit after psoriasis drug linked to suicide fears

By Ben HirschlerLONDON (Reuters) - AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller.Amgen , its partner on the project, announced late on Friday it was ending a collaboration to develop brodalumab after suicidal thoughts ...

Tags: AstraZeneca hit after psoriasis drug linked to suicide fears,  Amgen Latest News

MAY 25, 2015 - Zacks Investment Research

A Must Read - Share

AstraZeneca, Amgen End Psoriasis Drug Brodalumab Deal - Analyst Blog

AstraZeneca's (AZN) co-development and commercialization agreement with Amgen for brodalumab terminated, due to safety issues.

Tags: AstraZeneca, Amgen End Psoriasis Drug Brodalumab Deal - Analyst Blog,  Amgen Latest News